METAP2 and obesity due to melanocortin 4 receptor deficiency: Building on this foundation, this review aims to focus on six representative MetAP2 inhibitors with preclinical or clinical research outcomes for type 2 diabetes and obesity, exploring their mechanisms of action, therapeutic potential, and results from these studies.